Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.

[1]  A. Dey.  World report on ageing and health , 2017, The Indian Journal of Medical Research.

[2]  E. Franco,et al.  Human papillomavirus testing versus cytology in primary cervical cancer screening: End‐of‐study and extended follow‐up results from the Canadian cervical cancer screening trial , 2016, International journal of cancer.

[3]  Y. Qiao,et al.  Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline , 2016, Journal of global oncology.

[4]  M. Hakama,et al.  Age‐related incidence of cervical cancer supports two aetiological components: a population‐based register study , 2016, BJOG : an international journal of obstetrics and gynaecology.

[5]  C. Wheeler,et al.  Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study , 2016, International journal of cancer.

[6]  M. Søgaard,et al.  Global epidemiology of hysterectomy: possible impact on gynecological cancer rates. , 2015, American journal of obstetrics and gynecology.

[7]  T. Iftner,et al.  Long‐term risk of cervical intraepithelial neoplasia grade 3 or worse according to high‐risk human papillomavirus genotype and semi‐quantitative viral load among 33,288 women with normal cervical cytology , 2015, International journal of cancer.

[8]  F. Bray,et al.  50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence , 2014, British Journal of Cancer.

[9]  P. Gravitt,et al.  Increased age and race‐specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009 , 2014, Cancer.

[10]  Clare Gilham,et al.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials , 2014, The Lancet.

[11]  E. Franco,et al.  Counterpoint: cervical cancer screening guidelines--approaching the golden age. , 2013, American journal of epidemiology.

[12]  N. Weiss,et al.  Point-Counterpoint Point: Cervical Cancer Screening Guidelines Should Consider Observational Data on Screening Efficacy in Older Women , 2013 .

[13]  A. Stang.  Impact of hysterectomy on the age-specific incidence of cervical and uterine cancer in Germany and other countries. , 2013, European Journal of Public Health.

[14]  M. Tonelli,et al.  Cervical screening , 2013, Canadian Medical Association Journal.

[15]  M. Schiffman,et al.  Benchmarking CIN 3+ Risk as the Basis for Incorporating HPV and Pap Cotesting into Cervical Screening and Management Guidelines , 2013, Journal of lower genital tract disease.

[16]  D. Taylor,et al.  Population-based evaluation of type-specific HPV prevalence among women in British Columbia, Canada. , 2013, Vaccine.

[17]  M. Tonelli,et al.  Recommendations on screening for cervical cancer , 2013, Canadian Medical Association Journal.

[18]  A. Miller,et al.  Reduced cervical cancer incidence and mortality in Canada: national data from 1932 to 2006 , 2012, BMC Public Health.

[19]  Evan R. Myers,et al.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer , 2012, Journal of lower genital tract disease.

[20]  Thomas C Wright,et al.  Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. , 2011, The Lancet. Oncology.

[21]  E. Franco,et al.  Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada , 2011 .

[22]  M. van Ballegooijen,et al.  Trends in cervical cancer in the Netherlands until 2007: Has the bottom been reached? , 2011, International journal of cancer.

[23]  Diane Solomon,et al.  Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. , 2010, Journal of the National Cancer Institute.

[24]  P. Sparén,et al.  Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. , 2008, Journal of the National Cancer Institute.

[25]  Stephen D Walter,et al.  Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. , 2007, The New England journal of medicine.

[26]  J. Cuzick,et al.  Overview of the European and North American studies on HPV testing in primary cervical cancer screening , 2006, International journal of cancer.

[27]  J. Peto,et al.  The cervical cancer epidemic that screening has prevented in the UK , 2004, The Lancet.

[28]  Vic Hasselblad,et al.  Accuracy of the Papanicolaou Test in Screening for and Follow-up of Cervical Cytologic Abnormalities , 2000, Annals of Internal Medicine.

[29]  M. Fahs,et al.  Cost Effectiveness of Cervical Cancer Screening for the Elderly , 1992, Annals of Internal Medicine.